OC in the ER

Emergency Room Ovarian Cancer Diagnoses

Study: Population-based cohort of 28,204 women (England, 2017–2021). Access Full Study

The Bottom Line

An astonishing 40% (2 in 5) of ovarian cancer patients are diagnosed within 28 days of an emergency room admission. This represents a systemic failure that almost always results in late-stage diagnoses and poor survival rates.

Who is Missing the Diagnostic Window?

The data show emergency presentations aren't random; they split into two clear, vulnerable groups:

• The Disadvantaged Young: Younger women from low socioeconomic backgrounds facing barriers to primary medical care.

• The Frail Elderly: Older women with complex, competing comorbidities that mask vague cancer symptoms.

The Pandemic Spike: Emergency diagnoses peaked sharply in 2020, proving that when routine primary care access shrinks, emergency cancer presentations surge.

What OCA Support Nurses Need to Know

• High-Distress Intake: ER-diagnosed patients skip the gradual preparation period. They hit the oncology system in acute psychological shock with advanced disease. They need immediate, high-intensity supportive care.

• Vigilance for Vulnerable Demographics: Use these two specific patient profiles to trigger higher clinical suspicion when talking to patients with persistent, vague abdominal complaints.

• System Advocacy: Support nurses should push for lower triage thresholds for pelvic ultrasounds and CA-125 tests in emergency departments when treating women with unexplained GI or pelvic symptoms.

Quick Tags:

#Epidemiology #EmergencyPresentation #HealthEquity #EarlyDetection

Falling incidence of ovarian cancer and oophorectomy

Oophorectomy-Corrected Ovarian Cancer Incidence, Survival, and Mortality by Subtype, Race, Ethnicity

https://tinyurl.com/tk4v75pj

Ovarian cancer is declining. This decrease is mostly attributed to hormonal contraception, which means fewer lifetime menstrual cycles. This effect has been noted for the almost 60 years that hormonal contraception has been available and has increased with time as the users aged. As other forms of contraception develop, oral hormonal contraception is now used by 11% of the US population.

Despite this, the incidence of ovarian cancer continues to fall; the reasons are not clear. One suggestion is that removal of ovaries (oophorectomy) for reasons other than cancer may have the effect of reducing ovarian cancer. This study looked at the SEER cancer registry. Almost 160000 cases of ovarian cancer were recorded during the period 2002-2019. The rate of ovarian cancer decreased by about 2% for white women and less, about 1.5% for black women.

The rate of prior oophorectomy for elderly women (aged 70+) remained stable at about 30%. If the population numbers are adjusted to allow for the oophorectomy, no further decrease in ovarian cancer incidence is seen.

The authors note that there has been an increase in fallopian duct cancer, especially for black women and that some of the decrease in ovarian cancer may be due to reclassification. Other factors such as decreased menstrual hormonal therapy and the longer lives of the oral contraception generation may be part of the reason for the decline; it remains unclear as to why this is so.

Long-term PARPi therapy

Long-Term Outcomes in Patients with Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

https://tinyurl.com/y937k685

When PARP inhibitor therapy was first introduced, it was supposed to be maintenance treatment aimed at slowing the progression of ovarian cancer. The measure of success was held to be progression-free survival; cure was not expected with most, if not all, patients with ovarian cancer dying from the disease.

It soon became clear that there was a subgroup of patients whose survival was prolonged beyond the 5-year “cure” marker. This was noted in all the clinical trials with up to 20% of participants in the SOLO2 still alive 5 years later.

This retrospective study was of 320 patients who were part of this group, with a history of exceptional survival. About two-thirds of them had received continual treatment with PARP inhibitors; the others had discontinued the drug either due to carer intervention or due to adverse effects or personal preference. The median treatment course was 75 months; the 10-year progression-free survival was almost 80%.

Survival after cancer for this period may be deemed as a cure. It is of note that those exceptional survivors who terminated the treatment early had no worse outcomes. Why this group is exceptional remains unclear, previous work has suggested that a particular location of the DNA mutation of the BRCA gene may be protective. There was no difference between BRCA1 and 2 germline mutations. No increase in marrow dysfunction or myeloid leukaemia is noted with the incidence being small at less than 2%. For some patients, PARP inhibition may be curative. Interruption of treatment does not appear to be harmful.